<DOC>
	<DOCNO>NCT01632852</DOCNO>
	<brief_summary>This first human , prospective , multicenter , nonrandomized , open-label , dose-escalation study investigate safety , pharmacokinetics , pharmacodynamics immunogenicity repeat dose CSL362 .</brief_summary>
	<brief_title>A Study CSL362 Patients With CD123+ Acute Myeloid Leukemia Currently Remission</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female age 18 year old . Previous diagnosis CD123+ acute myeloid leukemia ( AML ) , de novo secondary . Completed recover planned induction consolidation therapy accord institution 's standard care , achieve complete remission ( CR ) /CR incomplete platelet recovery ( CRp ) ; either first second CR . Has factor confer high risk relapse . No plan additional postremission chemotherapy . Not currently candidate allogeneic hematopoietic stem cell transplant ( HSCT ) . Diagnosis acute promyelocytic leukemia ( APL ) . Known leukemic involvement central nervous system . Life expectancy 4 month less estimate investigator . Concurrent treatment plan treatment anticancer therapy ( chemotherapy , immunotherapy , radiotherapy , target therapy , gene therapy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>